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Background: Bone marrow mesenchymal stem cells (BM-MSCs) have been identified to be closely associated with
tumor growth and progression. However, the roles of tumor-resident MSCs in cancer have not been thoroughly
clarified. This study was to investigate the regulating effect of gastric cancer-derived MSCs (GC-MSCs) on gastric
cancer and elucidate the underlying mechanism.
Methods: GC-MSCs were isolated from primary human gastric cancer tissues and characterized. The effect of
GC-MSCs on gastric cancer cell proliferation was analyzed by MTT assay and colony formation assay. Transwell
migration assay was performed to evaluate the influence of GC-MSCs in gastric cancer cell migration. The regulating
effects of interactions between gastric cancer cells and GC-MSCs on their pro-angiogenic abilities were analyzed in a
co-culture system, with the expression, and secretion of pro-angiogenic factors detected by RT-PCR and Luminex assay.
Tube formation assay was used to further validate the angiogenic capability of gastric cancer cells or GC-MSCs. Cytokine
profiles in the supernatant of GC-MSCs were screened by Luminex assay and neutralizing antibody was used to identify
the key effective cytokines. The activations of Akt and Erk1/2 in gastric caner cells were detected by Western blot.
Results: GC-MSC treatment enhanced the proliferation and migration of BGC-823 and MKN-28 cells, which was more
potently than MSCs from adjacent non-cancerous tissues (GCN-MSCs) or bone marrow (BM-MSCs). Higher expression
levels of pro-angiogenic factors were detected in GC-MSCs than GCN-MSCs or BM-MSCs. After 10 % GC-MSC-CM
treatment, BGC-823, and MKN-28 cells expressed increased levels of pro-angiogenic factors and facilitated tube
formation more potently than cancer cells alone. Furthermore, GC-MSCs produced an extremely higher level of
interleukin-8 (IL-8) than GCN-MSCs or BM-MSCs. Blockade of IL-8 by neutralizing antibody significantly attenuated
the tumor-promoting effect of GC-MSCs. In addition, 10 % CM of IL-8-secreted GC-MSCs induced the activations of
Akt or Erk1/2 pathway in BGC-823 and MKN-28 cells.
Conclusion: Tumor-resident GC-MSCs promote gastric cancer growth and progression more efficiently than GCN-MSCs
or BM-MSCs through a considerable secretion of IL-8, which could be a possible target for gastric cancer therapy.
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Gastric cancer is one of the most frequent malignant
tumors and a leading cause of cancer death worldwide [1].
Although recent improvements have resulted in a
decrease in the mortality of gastric cancer, it remains a
serious health problem with poor prognosis [2–4].
Deficiency of targeted agents seems to restrict the
therapeutic strategy for gastric cancer and a thorough
understanding of the mechanism is urgently needed.
Tumor microenvironment (TME) has been indicated to
play a critical role in both the initiation and progression of
tumors [5–7]. Beside of soluble molecules, TME is
composed of various kinds of cells, such as fibroblasts,
tumor-associated macrophages, and endothelial cells [8].
Interactions between tumor cells and the surrounding
TME contribute to the growth and metastasis of tumors
[9, 10]. Thus, better understanding of the association
between gastric cancer cells and components in TME could
be directory for elucidating the underlying mechanisms of
gastric cancer.
As one of the key components in TME, mesenchymal
stem cells (MSCs) have attracted much attention and
have been demonstrated to affect the fate of tumor cells
in several reports [11–13]. A growing body of evidence
indicates that MSCs is closely associated with the initiation,
growth, and metastasis of various types of tumors. It
has been demonstrated that bone marrow-derived
MSCs (BM-MSCs) are capable to promote growth
and angiogenesis in both breast and prostate tumors
through the crosstalk between BM-MSCs and tumor cells
[14]. Another report indicated that lymphoma-derived
MSCs could promote tumor development by recruiting
monocytes into the inflammatory TME [15]. In addition,
gastric submucosa-resident mesenchymal stem cells have
been shown to contribute to cancer stroma formation and
play an important role in gastric cancer progression
[16]. However, the potential roles of gastric cancer-
derived MSCs (GC-MSCs) in gastric cancer and the exact
mechanisms have not been thoroughly investigated.
As a multifunctional pro-inflammatory cytokine,
interleukin-8 (IL-8) could increase cancer cells prolifera-
tion and migration [17, 18], stimulate tumor angiogenesis
[19] and induce epithelial-mesenchymal transition of
cancer cells [20]. The level of IL-8 has been demonstrated
to be indicative of poor prognosis in gastric cancer [21].
However, the underlying mechanisms of IL-8-medicated
gastric cancer progression are still obscure. Recently, the
role of IL-8 in the interactions between gastric cancer cells
and MSCs has drawn much interest. Kidney cancer cell
secreted IL-8 has been demonstrated to promote migra-
tion of BM-MSCs by activating the Akt signaling pathway
[22]. Another report indicated that IL-8 could enhance
the angiogenic potential of human BM-MSCs by stimu-
lating VEGF production [23]. Nevertheless, the role ofIL-8 in the regulating effect of tumor resident-MSCs
on gastric cancer cells has not been studied.
In this study, we isolated GC-MSCs from primary human
gastric cancer tissues, characterized their phenotype,
and studied their effect on gastric cancer growth and
progression in comparison to adjacent non-cancerous
tissues-derived MSCs (GCN-MSCs) and BM-MSCs.
Furthermore, molecular mechanisms involved in the tumor-
promoting effect of GC-MSCs were also investigated.
Materials and methods
Cells
GC-MSCs were isolated as described previously [24]
with a minor modification. Gastric cancer tissues were
obtained from patients who underwent radical gas-
trectomy in the First People’s Hospital of Lianyungang
(Jiangsu, China), and the procedure was approved by
the Ethics Committee of the First People’s Hospital of
Lianyungang. Briefly, fresh tumor tissues were collected
and washed off the blood. After rinsed in antibiotics to
avoid contamination, the tissue specimens were cut into
1-mm3-sized pieces and placed directly into culture dishes
for 30 min to improve adhesion. Then, the tissue explants
were floated in growing medium of L-DMEM (Gibco,
Invitrogen Corporation, Carlsbad, CA, USA) containing
15 % (v/v) fetal bovine serum (FBS; Gibco), penicillin
(100 U/ml), and streptomycin (100 μg/ml), and subse-
quently incubated at 37 °C in humid air with 5 % CO2.
When the fibroblast-like cells reached subconfluence, tis-
sue pieces were removed, and adherent cells were digested
and passaged into flasks for further expansion. At 4 to 5
passages, a homogeneous cell population was obtained
and used for the subsequent experiments. Paired adjacent
non-cancerous tissues located more than 5-cm away from
the tumor site were collected from the same patients for
GCN-MSCs isolation, which was performed in a similar
manner to GC-MSCs. GCN-MSCs and bone marrow
mesenchymal stem cells (BM-MSCs) were chosen as the
controls.
Human gastric cancer cell lines of BGC-823 and
MKN-28 were gifts from the First Affiliated Hospital
of Soochow University (Jiangsu, China). Cells were
cultured in RPMI 1640 medium (Gibco) supplemented
with 10 % (v/v) FBS in 5 % CO2 humidified atmos-
phere at 37 °C.
Osteogenic and adipogenic differentiation
GC-MSCs (passage 4) were seeded in a 6-well plate at
3 × 104 cells/cm2 and cultured in L-DMEM containing
15 % FBS. For osteogenic differentiation, GC-MSCs were
cultured in human mesenchymal stem cell osteogenic
differentiation medium (Cyagen Biosciences, Sunnyvale,
CA, USA) for 14 days and stained with alizarin red S to
detect calcium deposits. For adipogenic differentiation, cells
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(Cyagen Biosciences) for 21 days when the cells reach
100 % confluent or post confluent, and stained with Oil
red O solution to identify the presence of lipid-rich
vacuoles.
Flow cytometry
To identify the isolated fibroblast-like cells, flow cytometric
analysis was applied for detecting their immunophenotype.
In brief, cells at passage 4 were trypsinized and cell suspen-
sion containing 1 × 105 cells were incubated with the
monoclonal antibodies against CD14, CD34, and CD45
(FITC-conjugated); CD29, CD44, CD90, and CD105
(PE-conjugated) (BD Biosciences, San Jose, CA, USA) for
30 min at 4 °C in the dark. After washing, the labeled cells
were resuspended in PBS and analyzed on a FACSCanto
II flow cytometer (BD Biosciences, Sparks, MD, USA).
Isotype-matched antibodies with the corresponding
fluorescent labeling were used for measuring the non-
specific background signals.
Generation of conditioned medium
GC-MSCs were plated in 35 cm2 flasks and grown in
L-DMEM with 15 % FBS. Once reaching 80 % confluence,
the cells were washed with PBS and re-incubated with
4 ml complete medium at 37 °C with 5 % CO2. After
48 hrs, the conditioned medium (CM) was collected, spun
to remove cellular debris (1200 rpm for 10 min) and passed
through a 0.22 μm filter. Aliquots were frozen and stored
at -140 ˚C until use. GCN-MSC-, BM-MSC-, or gastric
caner cell-derived CM was generated in a similar manner.
MTT assay
BGC-823 or MKN-28 cells were plated into a 96-well
plate at 3 × 103 cells/well and cultured overnight.
Afterwards, the medium was aspirated off and cells
were treated with 10 % CM from GC-MSCs, GCN-MSCs,
or BM-MSCs, respectively. After incubation for 48 hrs,
MTT solution (5 mg/ml) was added into each well and
incubated with the cells at 37 °C for 4 hrs. Then the solu-
tion was discarded and 150 μl dimethyl sulfoxide (DMSO)
was added into the remaining cells for dissolving
formazan crystals. The optical density (OD) at 490 nm
was measured by a microplate reader (Benchmark,
Bio-Rad Laboratories, Hercules, CA, USA), and all the
experiments were performed in triplicate.
Colony forming units assay
For colony forming units (CFU) assay, BGC-823, or
MKN-28 cells were plated in duplicate at 200 cells/well
in a 24-well plate. To evaluate the effect of paracrine
factors, tumor cells were incubated in 10 % CM from
GC-MSCs, GCN-MSCs, or BM-MSCs, respectively.
Cultures were grown at 37 °C in a humidified incubatorwith 5 % CO2 for 10 days. Afterwards, the adherent cells
were washed with PBS, fixed with 4 % paraformaldehyde
and stained with 0.5 % Crystal violet for 10 min. Cluster
of ≥ 50 cells were considered as colonies.
Transwell migration assay
BGC-823 or MKN-28 cells were plated at 4 × 104 cells/well
in 8.0-mm pore sized 24-well Transwell inserts with
serum-free L-DMEM. Control medium or 10 % CM from
GC-MSCs, GCN-MSCs, or BM-MSCs was added into the
lower chamber of transwell dishes and incubated at 37 °C
for 16 hrs. After cell migration, the inserts were discarded,
and upper side of the filter was swabbed to remove the
nonmigratory cells. The filters were then fixed in 4 %
paraformaldehyde and stained with 0.5 % Crystal violet
for 20 min. Microscopic examination was performed and 8
randomly non-overlapping high-power fields (HPFs, × 200)
were selected to count the stained migrated cells. All the
experiments in each group were performed in triplicate.
RT-PCR analysis
To investigate the pro-angiogenic effect of gastric cancer
cells affected by MSCs, BGC-823, and MKN-28 cells were
treated with 10 % CM from GC-MSCs, GCN-MSCs, or
BM-MSCs, respectively. Conversely, the there different
types of MSCs were also exposed to 10 % CM collected
from BGC-823 and MKN-28 cells. Cells cultured in
control medium served as the controls. After 72 hrs
culture, cells in each group were harvested in TRIzol
reagent (Life Technologies, Invitrogen, Carlsbad, CA, USA),
and total RNA was extracted. A NanoDrop-2000 spectro-
photometer (ThermoScientific, Waltham, MA, USA) was
used to determine the yield and purity of total RNA.
Following the manufacturer’s instructions, 3 μg RNA was
processed for cDNA synthesis with Superscript II reverse
transcriptase (Roche Diagnostics, Indianapolis, IN, USA) in
a 40 μl reaction volume. PCR was performed in a reaction
mixture of 25 μl volume containing 12.5 μl Premix Ex Taq
(Takara, Shiga, Japan), 1 μl each primer (10 μM) and 2 μl
cDNA samples. Primers of human VEGF, MIP-2, TGF-β1,
IL-6, IL-8, and β-actin were designed using the Primer
Software as shown in Table 1, and amplification was
performed on the Veriti 96 Well Thermal Cycler (Applied
Biosystems, Foster City, CA, USA). The expression levels
of pro-angiogenic factors in BGC-823 and MKN-28 cells
exposed to GC-MSC-CM pretreated with anti-IL-8 Ab
were also analyzed by RT-PCR.
Tube formation assay
Tube formation assay was further performed to evaluate
the regulating effect of GC-MSCs on tumor angiogenesis
of BGC-823 and MKN-28 cells. The procedure was carried
out according to a previously published method [14]
with slight modifications. Briefly, matrigel (50 μl/well,
Table 1 Primer sequences for the amplification of target genes




VEGF NM_001025366 For: 5′-TTGCCTTGCTGCTCTACCTC-3′ 198 60
Rev: 5′-CACAGGATGGCTTGAAGATG-3′
MIP-2 NM_002089 For: 5′-AACCGAAGTCATAGCCACAC-3′ 150 59
Rev: 5′-CAGGAACAGCCACCAATAAG-3′
TGF-β1 NM_000660 For: 5′-CACGTGGAGCTGTACCAGAA-3′ 114 61
Rev: 5′-CACAACTCCGGTGACATCAA-3′
IL-6 NM_000600 For: 5′-GAGGAGACTTGCCTGGTGAA-3′ 267 60
Rev: 5′-GCGCAGAATGAGATGAGTTG-3′
IL-8 NM_000584 For: 5′-ACCGGAAGGAACCATCTCAC-3′ 822 61
Rev: 5′-GTGGATCCTGGCTAGCAGAC-3′
β-actin NM_001101 For: 5′-TGGACTTCGAGCAAGAGATG-3′ 207 60
Rev: 5′-GGATGTCCACGTCACACTTC-3′
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96-well plate and incubated for 1 hr at 37 °C for matrix
formation. After that, human umbilical vein endothelial
cells (HUVECs) were seeded onto the gel at a density of
1.5 × 104 cells/well in α-DMEM with 10 % FBS, 10 % CM
from GC-MSCs, 10 % CM from cancer cells, and 10 %
CM from co-culture of GC-MSCs and cancer cells,
respectively. After incubation for 8 hrs, the cells were
visualized, and photographed by an inverted microscope
to evaluate the tube-like structure formation (× 100).
Luminex immunoassay
To indentify the key factors mediating the tumor-
promoting effect of GC-MSCs, we collected cell superna-
tants of GC-MSCs, GCN-MSCs, and BM-MSCs at 48 hrs
of cell cultivation and quantified the concentrations of 10
cytokines/chemokines by Luminex immunoassay. Moreover,
the levels of cytokines/chemokines secreted by BGC-823
cells treated with 10 % CM from MSCs or MSCs exposed
to 10 % BGC-823-CM were detected to confirm the effect
of interaction between gastric cancer cells and GC-MSCs
on tumor angiogenesis and progression. To make data com-
parable, the supernatants were harvested in a way that the
concentration and culture time were coincident.
For all supernatant samples, an aliquot was immediately
stored at -140 °C and subsequently thawed for the
multiplexed bead array immunoassay based on a Bio-Plex
200 platform (Bio-Rad Laboratories). Custom-designed
MILLIPLEXH human cytokine/chemokine 96-well plate
assays (Cat. # 96-HBK1, Millipore Corporation, Billerica,
USA) were performed according to the manufacturer’s
protocol.
Neutralization assay by IL-8 blockade
To evaluate the effect of IL-8 on gastric cancer progres-
sion prompted by GC-MSCs, neutralization assay wasperformed in our study. Briefly, BGC-823, or MKN-28
cells were treated with 10 % GC-MSC-CM alone or
together with a human IL-8 neutralizing antibody (R&D
Systems, Minneapolis, MN, USA) at a concentration of
10 μg/ml. Mixtures of GC-MSC-CM and anti-IL-8 Ab
were incubated at 4 °C overnight before being added to
BGC-823 or MKN-28 cells. The proliferation, migration,
and pro-angiogenesis abilities of gastric cancer cells were
assessed after IL-8 neutralizing antibody treatment.
Western blot
Cell extracts were prepared with RIPA buffer supplemented
with complete protease inhibitors. Aliquots of proteins
were separated in 12 % SDS-PAGE and transferred onto
PVDF membrane, which was blocked with 5 % (w/v)
blotting grade milk for 1 hr. Membranes were then incu-
bated with the primary antibodies overnight at 4 °C. Sources
of the primary antibodies were: anti-p-Akt, anti-Akt, anti-p-
p44/42 MAPK (Erk1/2), and anti-p44/42 MAPK (Erk1/2)
(Cell Signaling Technology, Beverly, MA, USA), and anti-β-
actin (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Statistical analysis
Results were expressed as mean ± SEM. Data were ana-
lyzed and plotted with GraphPad Prism software 6.0
(GraphPad Software, La Jolla, CA, USA). Statistic analysis
was performed by non-parametric Mann-Whitney U test
using SPSS 16.0 statistical software, and P-value < 0.05
was considered statistically significant.
Results
Isolation and characterization of GC-MSCs
After 7–14 days of primary culture, a small population
of fibroblast-like cells had migrated from gastric cancer
tissues and expended in vitro (Fig. 1A). After plated into
flasks, the cells exhibited spindle-shaped morphology,
Fig. 1 (See legend on next page.)
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Fig. 1 Characterization of human gastric cancer-derived MSCs. (A) Spindle-shaped cells migrated from gastric cancer tissues after 7–10 days of
primary culture (upper left) and fibroblast-like cells appeared at passage 4 of GC-MSCs culture (upper right) with the morphology similar to
GCN-MSCs (lower left) or BM-MSCs (lower right) (×40). (B) Representative photographs of GC-MSCs differentiated into mineralizing cells with
alizarin red S staining (upper) and adipogenic cells with Oil red O staining (lower) (×200, ×400). (C) Surface antigens expressed on GC-MSCs
analyzed by flow cytometry. (D) Surface antigens expressed on GCN-MSCs analyzed by flow cytometry
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Moreover, the pluripotent differentiation potential of
GC-MSCs was evaluated in vitro. After induction for
14 days, alizarin red S staining revealed that mineralized
extracellular matrix had generated in the cytoplasm of
GC-MSCs (Fig. 1B), suggesting osteoblastic differentiation
potential of GC-MSCs. On the other hand, the cells were
shown to be filled with lipid-rich vacuoles by Oil red O
staining after adipogenic induction (Fig. 1B). Furthermore,
flow cytometry analysis conveyed that both GC-MSCs and
GCN-MSCs were positive for CD29, CD44, CD90,
and CD105, but negative for CD14, CD34, and CD45
(Fig. 1C, D), which displayed the characteristic surface
markers of MSCs. Together, these data identifies the
MSC-like characteristics of GC-MSCs.
GC-MSCs facilitate the proliferation of gastric cancer cells
more potently than GCN-MSCs or BM-MSCs
We performed MTT assay and CFU assay to investigate
whether GC-MSCs could promote gastric cancer cell
growth and to compare the tumor-promoting activity of
GC-MSCs with MSCs from non-malignant tissues. As
indicated by the results of MTT assay, both BGC-823,
and MKN-28 cells showed significantly increases in cell
proliferation when cultured in 10 % CM from GC-MSCs,
GCN-MSCs, or BM-MSCs compared with the controlsFig. 2 Effect of GC-MSCs on gastric cancer cell proliferation analyzed by M
GC-MSCs, GCN-MSCs, or BM-MSCs. (B) Viability of MKN-28 cells cultured wit
**P < 0.01: compared with the control group; #P < 0.05, ##P < 0.01: compare(P < 0.05) (Fig. 2). Moreover, GC-MSCs displayed a
significantly higher potential in promoting gastric
caner cell proliferation than GCN-MSCs or BM-MSCs
(P < 0.05) (Fig. 2).
In accordance with MTT assay, CFU analysis revealed
that gastric cancer cells treated with 10 % CM from
GC-MSCs, GCN-MSCs, or BM-MSCs grew faster than
the controls (Fig. 3). Furthermore, 10 % GC-MSC-CM
treated BGC-823 and MKN-28 cells both showed higher
average colony numbers (P < 0.05) and formed lager
colonies than 10 % GCN-MSC-CM or BM-MSC-CM
treated group (Fig. 3), suggesting a markedly potent
tumor-promoting effect of GC-MSCs. Together, these
results suggest that MSCs isolated from gastric cancer
tissues could prompt gastric cancer cell proliferation more
potently than GCN-MSCs or BM-MSCs in vitro.
GC-MSCs promote the migration of gastric cancer cells
more efficiently than GCN-MSCs or BM-MSCs
We exploited transwell migration assay to investigate
the regulating effect of GC-MSCs on gastric cancer cell
migration. The number of viable cancer cells migrat-
ing into the lower chamber was the highest in 10 %
GC-MSC-CM treated group than the other groups
(Fig. 4). Although 10 % GCN-MSC-CM or BM-MSC-CM
also showed significantly improved recruitment effect onTT assay. (A) Viability of BGC-823 cells cultured with 10 % CM from
h 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs. *P < 0.05,
d with the GC-MSC-CM treated group
Fig. 3 Effect of GC-MSCs on gastric cancer cell proliferation assessed by CFU assay. (A) Representative images of BGC-823 cell colony formation
treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs. (B) Average colony numbers ± SD were plotted of BGC-823 cells in different groups
(n = 3). (C) Representative images of MKN-28 cell colony formation treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs. (D) Average
colony numbers ± SD were plotted of MKN-28 cells in different groups (n = 3). *P < 0.05: compared with the control group; #P < 0.05: compared
with the GC-MSC-CM treated group
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cells was observed upon exposure to 10 % GC-MSC-CM
and the number of tumor cells attracted by 10 %
GC-MSC-CM was strikingly higher than that by 10 %GCN-MSC-CM or BM-MSC-CM (P < 0.05) (Fig.4). Thus,
these data demonstrate that gastric cancer cells may be
preferentially recruited by GC-MSCs resident in the
tumor tissues.
Fig. 4 Effect of GC-MSCs on gastric cancer cell migration analyzed in a transwell system. (A) Representative images of migrated BGC-823 cells
treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs (×200). (B) The numbers of migrated BGC-823 cells ± SD were plotted in different
groups (n = 3). (C) Representative images of migrated MKN-28 cells treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs (×200). (D) The
numbers of migrated MKN-28 cells ± SD were plotted in different groups (n = 3). *P < 0.05, **P < 0.01: compared with the control group; #P < 0.05,
##P < 0.01: compared with the GC-MSC-CM treated group
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GCN-MSCs or BM-MSCs
As one of the key components in TME, MSCs have
been found to play a critical role in tumor vasc-
ularization. In this study, we firstly investigated, andcompared the mRNA expressions of pro-angiogenic
factors in GC-MSCs with MSCs from non-malignant
tissues. As shown in Fig. 5A, mRNA levels of VEGF,
MIP-2, TGF-β1, IL-6, and IL-8 were the highest in
GC-MSCs than those in GCN-MSCs or BM-MSCs,
Fig. 5 (See legend on next page.)
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Fig. 5 Regulating effect of interaction between BGC-823 cells and GC-MSCs on tumor angiogenesis. (A) RT-PCR analysis of VEGF, MIP-2, TGF-β1,
IL-6, and IL-8 expression in GC-MSCs, GCN-MSCs, or BM-MSCs. (B) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 expression in GC-MSCs,
GCN-MSCs, or BM-MSCs after exposed to 10 % BGC-823-CM for 3 days. (C) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 expression in
BGC-823 cells after treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs for 3 days. (D) Representative photographs of HUVECs seeded
on Matrigel for 8 hrs in culture medium (upper left) and in the presence of 10 % CM from GC-MSCs (upper right), BGC-823 cells (lower left), or
co-cultured BGC-823 cells and GC-MSCs (lower right) (×100). (E) Luminex assay of VEGF, IL-6, and IL-8 secretion in the supernatant of GC-MSCs,
GCN-MSCs, or BM-MSCs with 10 % BGC-823-CM treatment for 3 days. (F) Luminex assay of VEGF, IL-6, and IL-8 secretion in the supernatant of
BGC-823 cells after exposed to 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs for 3 days. *P < 0.05, **P < 0.01: compared with the control group;
#P < 0.05: compared with the GC-MSC-CM treated group
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GC-MSCs.
To investigate the effect of tumor cells on angio-
genesis ability of GC-MSCs, we detected the expres-
sions of pro-angiogenic factors by GC-MSCs, GCN-MSCs,
or BM-MSCs after treated with 10 % BGC-823-CM or
MKN-28-CM in vitro. The results of RT-PCR indicated
that there were no appreciable increases in the expression
of pro-angiogenic factors in GC-MSCs after exposed
to 10 % CM of gastric cancer cells, although the
expression of VEGF was slightly up-regulated. Conversely,
mRNA levels of VEGF, MIP-2, TGF-β1, IL-6, and IL-8
were all significantly up-regulated in GCN-MSCs or
BM-MSCs after 10 % BGC-823-CM or MKN-28-CM
treatment (Fig. 5B and Fig. 6A), suggesting a converted
progression of non-malignant MSCs by tumor cells. On
the other hand, Luminex assay demonstrated that the
secretions of pro-angiogenic factors VEGF and IL-8
were all significantly up-regulated in the supernatant
of GC-MSCs, GCN-MSCs, or BM-MSCs after 10 %
BGC-823-CM stimulation (P < 0.05) (Fig. 5E). Thus,
the above results suggest that GC-MSCs might play
an important role in tumor neovascularization and this
ability may be converted by gastric cancer cells in a
paracrine manner.
GC-MSCs enhance pro-angiogenesis ability of gastric
cancer cells more potently than GCN-MSCs or BM-MSCs
Given that GC-MSCs could potently enhance the pro-
liferation and migration of gastric cancer cells, we fur-
ther wondered whether they affected the pro-angiogenic
ability of tumor cells, which is considered as a critical step
for tumor progression. As shown in Fig. 5C, incubation
with 10 % CM from GC-MSCs or GCN-MSCs dramatic-
ally increased the expressions of VEGF, MIP-2, TGF-β1,
and IL-8 in BGC-823 cells compared with the control.
The similar effect was also confirmed in MKN-28 cells
(Fig. 6B). In addition, the results of Luminex immunoassay
showed that significantly elevated levels of VEGF and IL-8
were detected in the supernatant of BGC-823 cells treated
with 10 % GC-MSC-CM in comparison to the other
groups (P < 0.05) (Fig. 5F), suggesting a more effective
promoting role of GC-MSCs in tumor cell angiogenesis
than GCN-MSCs or BM-MSCs.On the other hand, the results of tube formation assay
demonstrated that 10 % CM from gastric cancer cells,
GC-MSCs, or co-cultured gastric cancer cells and
GC-MSCs enhanced tube formation by HUVECs com-
pared with the CM-free control (Fig. 5D and Fig. 6C).
Furthermore, exposure to 10 % CM from co-cultured
gastric cancer cells and GC-MSCs resulted in a more
branched network than 10 % gastric cancer cell-CM
or GC-MSC-CM alone (Fig. 5D and Fig. 6C), suggesting a
dramatically enhanced ability of co-cultured cells to induce
the formation of tube-like structure. Thus, our results
indicate that GC-MSCs could largely enhance the ability of
gastric cancer cells to prompt angiogenesis through
up-regulation of the pro-angiogenic factors.
IL-8 secretion is strikingly high in the supernatant
of GC-MSCs
Since GC-MSCs were demonstrated to affect proliferation,
migration, and angiogenesis of gastric cancer in a paracrine
manner, the key factors contributing to the tumor-
promoting role of GC-MSCs were further analyzed in this
study. Cytokines/chemokines including VEGF, MCP-1,
IL-6, and IL-8 were detectable in the supernatant of
GC-MSCs, GCN-MSCs, or BM-MSCs, whereas GC-MSCs
elaborated a strikingly higher level of IL-8 secretion with
significant difference from GCN-MSC-CM or BM-MSC-
CM (P < 0.01) (Fig. 7A). Along these lines, we postulate
that the tumor-promoting effect of GC-MSCs may be
partly mediated by IL-8 secretion.
Anti-IL-8 antibody attenuates the gastric
cancer-promoting effect of GC-MSCs
Since IL-8 is reported to play a paramount role in tumor
progression and strikingly high level of IL-8 was
detected in the supernatant of GC-MSCs in our study, we
wondered whether IL-8 mediated the tumor-promoting
effect of GC-MSCs in gastric cancer. The results of MTT
assay indicated that simultaneous treatment with 10 %
GC-MSC-CM and anti-IL-8 antibody resulted in a signifi-
cant decrease in the proliferation of BGC-823 or MKN-28
cells compared with 10 % GC-MSC-CM treated group
(P < 0.05) (Fig. 7B and Fig. 6D). In addition, the num-
ber of BGC-823, or MKN-28 cells attracted by 10 %
GC-MSC-CM was dramatically reduced by anti-IL-8
Fig. 6 Pro-angiogenesis and tumor-promoting effect of GC-MSC-secreted IL-8 on MKN-28 cells. (A) RT-PCR analysis of VEGF, MIP-2, TGF-β1, IL-6,
and IL-8 expression in GC-MSCs, GCN-MSCs, or BM-MSCs after exposed to 10 % MKN-28-CM for 3 days. (B) RT-PCR analysis of VEGF, MIP-2, TGF-β1,
IL-6, and IL-8 expression in MKN-28 cells after treated with 10 % CM from GC-MSCs, GCN-MSCs, or BM-MSCs for 3 days. (C) Representative
photographs of HUVECs seeded on Matrigel for 8 hrs in culture medium and in the presence of 10 % CM from GC-MSCs, MKN-28 cells, or co-cultured
MKN-28 cells and GC-MSCs (×100). (D) Viability of MKN-28 cells cultured in 10 % GC-MSC-CM treated with or without anti-IL-8 antibody by MTT assay.
(E) Transwell migration assay of MKN-28 cells exposed to 10 % GC-MSC-CM with or without anti-IL-8 antibody treatment (×200). (F) Expression of VEGF,
MIP-1, IL-6, and IL-8 in MKN-28 cells exposed to 10 % GC-MSC-CM with or without IL-8 blockade. (G) Western blot for protein levels of Akt, p-Akt,
p44/42 MAPK (Erk1/2), and p-p44/42 MAPK (Erk1/2) in MKN-28 cells stimulated by 10 % GC-MSC-CM with or without IL-8 blockade
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we investigated the role of IL-8 in gastric cancer
angiogenesis promoted by GC-MSCs. As shown in
Fig. 7D, increased expressions of VEGF, MIP-2, IL-6,
and IL-8 in BGC-823 cells by 10 % GC-MSC-CM were
abrogated in the presence of IL-8-specific neutralizing
antibody. Similar results were also obtained in MKN-28
cells (Fig. 6F). Accordingly, anti-IL-8 blockade markedlyattenuated the formation of tube-like structures by
HUVECs after 10 % GC-MSC-CM stimulation (Fig. 7F).
In addition, Western blot analysis revealed that 10 %
GC-MSC-CM also led to increased phosphorylation
of Akt or p44/42 MAPK (Erk1/2) in gastric cancer cells,
which was partly abrogated by IL-8-specific neutralizing
antibody treatment (Fig. 7E and Fig. 6G). Thus, our data
indicate that the tumor-promoting effect of GC-MSCs is
Fig. 7 (See legend on next page.)
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Fig. 7 Tumor-promoting effect of GC-MSCs on BGC-823 cells is attenuated by the application of anti-IL-8 antibody. (A) Cytokine profile analysis of
GC-MSCs, GCN-MSCs, or BM-MSCs by Luminex immunoassay. (B) Viability of BGC-823 cells cultured in 10 % GC-MSC-CM treated with or without
anti-IL-8 antibody by MTT assay. (C) Transwell migration assay of BGC-823 cells exposed to 10 % GC-MSC-CM with or without anti-IL-8 antibody
treatment (×200). (D) Expression of VEGF, MIP-1, IL-6, and IL-8 in BGC-823 cells exposed to 10 % GC-MSC-CM with or without IL-8 blockade.
(E) Western blot for protein levels of Akt, p-Akt, p44/42 MAPK (Erk1/2), and p-p44/42 MAPK (Erk1/2) in BGC-823 cells stimulated by 10 %
GC-MSC-CM with or without IL-8 blockade. (F) Representative photographs of capillary tube formation by HUVECs exposed to 10 % GC-MSC-CM with or
without IL-8 blockade. (×100). *P< 0.05, **P< 0.01: compared with the control group; #P< 0.05, ##P< 0.01: compared with the GC-MSC-CM treated group
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which suggests a critical role of IL-8 in gastric caner
progression mediated by GC-MSCs.
Discussion
During the past decades, correlation between MSCs,
and tumor has drawn a lot of attention and been reported
to play a critical role in tumor progression. Upon tumori-
genesis, non-cancerous tissues-derived MSCs such as
BM-MSCs are recruited into tumor mass and incorporate
into the stromal microenvironment [25, 26]. After
continuously exposed to inflammatory factors and
other stromal cells in local tumor tissues, BM-MSCs
may be instructed to adopt some new features and
become tumor-resident MSCs [27, 28]. Although consider-
able studies have performed to investigate the correlation
between non-cancerous tissues-derived MSCs and
tumor [29–31], the detailed properties of converted
tumor-resident MSCs and their role in tumor growth
and progression merit further investigation.
Gastric cancer is one of the most frequent malignant
tumors, which has affected humans for millennia.
Despite the improved prognosis, overall 5-year survival
rates for patients of gastric cancer remain disappointing.
For new therapeutic strategies development, an improved
understanding of the mechanisms in gastric cancer growth
and progression is urgently needed. In this study, we
isolated resident MSCs from human gastric cancer tissues,
which showed a multi-lineage differentiation potential
and a heterogeneous immunophenotype with fibroblastic
morphology. We studied the promoting effect of GC-MSCs
on the proliferation, migration, and pro-angiogenic
capabilities of gastric cancer cells in vitro and compared it
with non-malignant tissue-derived GCN-MSCs and
BM-MSCs. In addition, we further investigated the
underlying mechanism involved in the tumor-promoting
effect of GC-MSCs.
Firstly, we observed the influence of GC-MSCs in gastric
cancer cell proliferation. The results showed that BGC-823
and MKN-28 cells were both stimulated to grow faster
when incubated with 10 % GC-MSC-CM, which dis-
played a more potent tumor-promoting ability than
GCN-MSC-CM or BM-MSC-CM. This suggests a pivotal
role of gastric cancer-resident MSCs in tumor cell
proliferation. In keeping with our results, Guangwen,and colleagues reported that mouse lymphoma-derived
MSCs present a more potently effect of tumor growth-
promotion than BM-MSCs or MSCs from other normal
tissues such as skin [16]. Another study also conveyed that
MSCs from human breast cancer tissues have certain
increased effect on the growth of breast cancer in vitro
[32]. Consequently, we investigated the effect of GC-MSCs
on gastric cancer cell recruitment by a transwell mi-
gration assay. A more drastic promotion was ob-
served in the migration of gastric cancer cells with
10 % GC-MSC-CM stimulation compared with 10 %
GCN-MSC-CM or BM-MSC-CM treatment, suggesting
a greater potential of GC-MSCs to promote gastric cancer
metastasis.
Furthermore, the pro-angiogenic role of GC-MSCs has
drawn much interest in the present study, which may be
involved in gastric cancer growth and metastasis. Ting
and colleagues found that the crosstalk between tumor
cells and BM-MSCs could increase the expression of
pro-angiogenic factors and thereby promote growth and
angiogenesis of breast and prostate tumors [14]. Another
report proposed that MSC-secreted IL-6 may enrich the
pro-angiogenic factors secreted by cancer cells to
increase angiogenesis and tumor growth, and targeting this
interaction may lead to novel therapeutic and preventive
strategies [33]. In our study, GC-MSCs expressed higher
levels of VEGF, MIP-2, TGF-β1, IL-6, and IL-8 than
GCN-MSCs or BM-MSCs did, suggesting a more potent
role of GC-MSCs in tumor angiogenesis. Consequently,
we investigated the effect of gastric cancer cell-derived
CM on the pro-angiogenic ability of GC-MSCs and
observed an appreciable increase of VEGF both in mRNA
and protein levels. Moreover, the expressions of VEGF,
MIP-2, TGF-β1, IL-6, and IL-8 were all up-regulated in
GCN-MSCs and BM-MSCs by 10 % BGC-823-CM or
MKN-28-CM stimulation, suggesting a converted pro-
gression suffered by MSCs from non-malignant tissues by
tumor cells. On the other hand, BGC-823, or MKN-28
cells exposed to 10 % GC-MSC-CM presented appre-
ciable increase in pro-angiogenic ability, which may be
associated with the promotions of growth and metastasis
in gastric cancer.
How did GC-MSCs stimulate the proliferation, migra-
tion, and angiogenesis of gastric cancer cells? The
underlying mechanism was further investigated in our
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IL-8 could stimulate VEGF production in BM-MSCs in
part via the PI3K/Akt and MAPK/ERK signal pathways
and administration of IL-8 treated BM-MSCs increases
angiogenesis after stroke [23]. Ko and colleagues
reviewed that IL-8 induced by H. pylori displays a major
role in gastric cancer development and progression, and
may be indicative of poor prognosis [19]. However,
the mechanism has not been thoroughly understood
in the context of gastric cancer. Our results of Luminex
assay conveyed that the level of IL-8 was strikingly high in
the secretome of GC-MSCs in comparison to GCN-MSCs
or BM-MSCs, suggesting a potential of IL-8 as the key
mediator for tumor-promoting activity of GC-MSCs.
Furthermore, we demonstrated that the improved
abilities of proliferation, migration, and angiogenesis
in gastric cancer cells regulated by GC-MSCs can be
attenuated by IL-8 neutralizing antibody. Furthermore,
we also observed that GC-MSCs increased the activa-
tions of Akt and p44/42 MAPK (Erk1/2) in gastric
cancer cells and this effect could be partly abrogated
in the presence of IL-8-specific neutralizing antibody,
indicating that GC-MSC-secreted IL-8 promoted gas-
tric cancer growth and progression through regulating
the signal pathways related to tumor growth and
angiogenesis. Thus, these observations imply that the
promoting effect of GC-MSCs on gastric cancer growth
and progression are attributed to their strikingly highly
secretion of IL-8. Blocking the interaction between
GC-MSCs and gastric cancer cells by anti-IL-8 anti-
bodies may provide a novel therapeutic or preventive
strategy.
However, there are potential limitations of our experi-
mental designs, as only two gastric cancer cell lines were
supplied in this study and further investigation is needed
to better understand the mechanisms related to cancer-
resident MSCs in other tumor models. In addition, the
in vivo experiments with mice model should be performed
in future for better understanding of the mechanism
underlying the tumor-promoting activity of IL-8-secreted
GC-MSCs.
Conclusions
Our present study demonstrates that gastric cancer-
resident MSCs have a potent ability in promoting the
proliferation, migration, and pro-angiogenesis of gas-
tric cancer cells. IL-8, which is largely secreted by
GC-MSCs, partly contributes to the tumor-promoting
effect of GC-MSCs. In conclusion, we propose a new
mechanism involved in gastric cancer that MSCs resident
in gastric cancer tissues play a paramount role in cancer
angiogenesis and progression through the secretion of
cytokine IL-8, which may provide a novel avenue for
gastric cancer therapy.Abbreviations
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